A new cancer vaccine has shown a 100 percent success rate when treating aggressive melanoma in mice.

一种新的癌症疫苗显示能100%成功治疗老鼠身体内的恶性黑色素瘤。

Researchers at Scripps Research Institute in La Jolla, Calif., and the University of Texas in Dallas, gave mice suffering from melanoma a cancer immunotherapy drug called anti-PD-L1, which prevents tumor cells from attacking their immune systems. The study found that rodents who were also given Diprovocim, a chemical compound that’s meant to galvanize the immune system, had a 100 percent survival rate.

加州拉霍亚市斯克里普斯研究所和达拉斯德州大学的研究人员给患有黑色素瘤的老鼠注射了一种名为PD-L1的癌症免疫治疗药物，这种药物可以防止肿瘤细胞攻击它们的免疫系统。研究发现，同时被注射一种叫Diprovocim的化学物质的老鼠有100%的存活率，Diprovocim可以刺激免疫系统。

And attempts to re-introduce cancer tumors in these vaccinated mice failed.

而且被接种疫苗的老鼠没法再被重新引入癌症肿瘤。

While more research needs to be done to determine the vaccine’s effectiveness in humans, researchers are hopeful about their findings.

虽然还需要做更多的研究来确定疫苗是否对人类有效，但研究人员对他们的发现充满希望。

“Just as a vaccine can train the body to fight off external pathogens, this vaccine trains the immune system to go after the tumor,” Dale Boger, a chemist at Scripps, wrote in a press release. “This co-therapy produced a complete response — a curative response — in the treatment of melanoma.”

斯克里普斯的化学家戴尔.博格在一份新闻稿中写道：“就像疫苗可以训练身体抵抗外部病原体一样，这种疫苗也可以训练免疫系统去对付肿瘤。这种联合治疗在治疗黑素瘤中产生了完全缓解，即治疗反应。”

According to the American Cancer Society, more than 9,000 people die of melanoma every year, and it accounts for about 1 percent of skin cancer diagnoses in the US.

据美国癌症协会统计，每年有9000多人死于黑素瘤，美国诊断出的皮肤癌患中，黑素瘤约占1%。